Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: Immunohistochemistry and chromogenic in situ hybridization

Pathology International

Volumn 58, Issue 1, 2008, Pages 17-25

  Cho, Eun Y ^a   Choi, Yoon La ^a   Han, Jae J ^a   Kim, Kyoung Mee ^a   Oh, Young L ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Chromogenic in situ hybridization; Cyclin D1; EGFR; Her2; Immunohistochemistry

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; BREAST NEOPLASMS; CHROMOGENIC COMPOUNDS; CYCLIN D1; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, BCL-1; GENES, ERBB-1; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 36649030622     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2007.02183.x     Document Type: Article

References (54)

1. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer. Prognostic factor, predictive factor, and target for therapy. Oncologist 1998 3 : 237 52.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 235 : 177 82.
3. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987 1 : 1398 402.
4. Nicholson S, Wright C, Sainsbury JR et al. Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure. J Steroid Biochem Mol Biol 1990 37 : 811 14.
5. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL. The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 1994 29 : 41 9.
6. Umekita Y, Ohi Y, Sagara Y, Yoshida H. Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer 2002 98 : 415 18.
7. Gillett C, Smith P, Gregory W et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 1996 69 : 92 9.
8. Knowlden JM, Hutcheson IR, Jones HE et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003 144 : 1032 44.
9. Thor A. HER2: A discussion of testing approaches in the USA. Ann Oncol 2001 12 : S101 7.
10. Pelosio P, Barbareschi M, Bonoldi E et al. Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann Oncol 1996 7 : 695 703.
11. Nahta R, Hortobagyi GN, Esteva FJ. Growth factor receptors in breast cancer: Potential for therapeutic intervention. Oncologist 2003 8 : 5 17.
12. Agrawal A, Gutteridge E, Gee JM, Nicholson RI, Robertson JF. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer 2005 12 : S135 44.
13. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001 411 : 1017 21.
14. Petty WJ, Dragnev KH, Dmitrovsky E. Cyclin D1 as a target for chemoprevention. Lung Cancer 2003 41 : S155 61.
15. Neve RM, Lane HA, Hynes NE. The role of overexpressed HER2 in transformation. Ann Oncol 2001 12 : S9 13.
16. Shia J, Klimstra DS, Li AR et al. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: An immunohistochemical and chromogenic in situ hybridization study. Mod Pathol 2005 18 : 1350 56.
17. Naidu R, Wahab NA, Yadav MM, Kutty MK. Expression and amplification of cyclin D1 in primary breast carcinomas: Relationship with histopathological types and clinico-pathological parameters. Oncol Rep 2002 9 : 409 16.
18. Buckley MF, Sweeney KJ, Hamilton JA et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993 8 : 2127 33.
19. Millar EK, Tran K, Marr P, Graham PH. p27KIP-1, cyclin A and cyclin D1 protein expression in ductal carcinoma in situ of the breast: P27KIP-1 correlates with hormone receptor status but not with local recurrence. Pathol Int 2007 57 : 183 9.
20. Tanner M, Gancberg D, Di Leo A et al. Chromogenic in situ hybridization: A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000 157 : 1467 72.
21. Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol 2002 15 : 657 65.
22. Bhargava R, Gerald WL, Li AR et al. EGFR gene amplification in breast cancer: Correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 2005 18 : 1027 33.
23. Reis-Filho JS, Savage K, Lambros MB et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: An immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 2006 19 : 999 1009.
24. Bhargava R, Lal P, Chen B. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: Does it measure up to fluorescence in situ hybridization? Am J Clin Pathol 2005 123 : 237 43.
25. Black MM, Speer FD, Opler SR. Structural representations of tumor-host relationships in mammary carcinoma; biologic and prognostic significance. Am J Clin Pathol 1956 26 : 250 65.
26. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991 19 : 403 10.
27. Frierson HF Wolber RA, Berean KW et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 1995 103 : 195 8.
28. Gupta D, Middleton LP, Whitaker MJ, Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol 2003 119 : 381 7.
29. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998 11 : 155 68.
30. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977 33 : 159 74.
31. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ. Tyrosine kinase signalling in breast cancer: Epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2000 2 : 203 10.
32. Qian X, LeVea CM, Freeman JK, Dougall WC, Greene MI. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: A mechanism of interreceptor kinase activation and transphosphorylation. Proc Natl Acad Sci USA 1994 91 : 1500 504.
33. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997 88 : 405 15.
34. Loring P, Cummins R, O'Grady A, Kay EW. HER2 positivity in breast carcinoma: A comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization. Appl Immunohistochem Mol Morphol 2005 13 : 194 200.
35. Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000 13 : 37 45.
36. Todorovic-Rakovic N, Jovanovic D, Neskovic-Konstantinovic Z, Nikolic-Vukosavljevic D. Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer. Pathol Int 2005 55 : 318 23.
37. Pauletti G, Dandekar S, Rong H et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000 18 : 3651 64.
38. Hammock L, Lewis M, Phillips C, Cohen C. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol 2003 34 : 1043 7.
39. Rampaul RS, Pinder SE, Wencyk PM et al. Epidermal growth factor receptor status in operable invasive breast cancer: Is it of any prognostic value? Clin Cancer Res 2004 10 : 2578.
40. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002 71 : 67 75.
41. Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocr Rev 1992 13 : 3 17.
42. Jirstrom K, Stendahl M, Ryden L et al. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 2005 65 : 8009 16.
43. Lammie GA, Fantl V, Smith R et al. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 1991 6 : 439 44.
44. Bilous M, Dowsett M, Hanna W et al. Current perspectives on HER2 testing: A review of national testing guidelines. Mod Pathol 2003 16 : 173 82.
45. Ridolfi RL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinoma: A combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 2000 13 : 866 73.
46. Thomson TA, Hayes MM, Spinelli JJ et al. HER-2/neu in breast cancer: Interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 2001 14 : 1079 86.
47. Ellis IO, Dowsett M, Bartlett J et al. Recommendations for HER2 testing in the UK. J Clin Pathol 2000 53 : 890 92.
48. Arnould L, Denoux Y, MacGrogan G et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 2003 88 : 1587 91.
49. Park K, Kim J, Lim S, Han S, Lee JY. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol 2003 16 : 937 43.
50. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005 103 : 1763 9.
51. Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004 10 : 4793 8.
52. Kumamoto H, Sasano H, Taniguchi T, Suzuki T, Moriya T, Ichinohasama R. Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: Application in screening of patients for trastuzumab (Herceptin) therapy. Pathol Int 2001 51 : 579 84.
53. Torregrosa D, Bolufer P, Lluch A et al. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. Clin Chim Acta 1997 262 : 99 119.
54. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005 5 : 341 54.